What Dexcom Ventures does

Dexcom Ventures is the corporate venture capital arm of Dexcom Inc. (NASDAQ: DXCM), a publicly-traded leader in continuous glucose monitoring technology. Founded circa 2021 and headquartered in San Diego alongside its parent, the fund is operated by a small team (1-10 employees) led by Managing Director Jason Halac and Analyst Adam Seivert, whose leadership draws on 20+ years of combined experience built inside Dexcom. Its stated mission is to invest in transformational technology platforms adjacent to or related to Dexcom's core diabetes care strategy, often through contrarian or symmetrical bets, in order to supplement growth in the parent company's core business while advancing development into chronic health conditions beyond diabetes.

Dexcom Ventures does not develop proprietary products or technology. Instead, it builds a portfolio of equity investments in early-stage healthcare technology companies, with six disclosed holdings: Medcrypt (medical device cybersecurity), Nutromics (Continuous Molecular Monitoring), Epitel (wearable seizure monitoring), Signos (AI-driven CGM app for weight management), BiointelliSense (medical-grade Remote Patient Monitoring Hospital at Home), and Beta Bionics (iLet Bionic Pancreas automated insulin delivery). Investment terms, check sizes, fund size, and round details are not publicly disclosed. The fund sources opportunities through technology scouting, strategic pipeline development, and co-investor networks, with deal flow sourced globally.

As a corporate venture subsidiary, Dexcom Ventures generates returns through equity realization events in portfolio companies — IPOs, acquisitions, or secondary sales — rather than recurring product or service revenue. Portfolio companies receive capital, strategic support, and access to Dexcom's distribution networks, regulatory expertise, and brand credibility, while Dexcom gains optionality on adjacent chronic-care and biosensing technologies. No AUM, management fees, carried interest, or realized returns are publicly disclosed for the entity.

Name

Dexcom Ventures

Legal name

Dexcom Ventures

Website

https://dexcomventures.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Dexcom Ventures is the corporate venture capital arm of Dexcom Inc., investing in early-stage healthcare technology companies in biosensing, remote monitoring, and chronic disease management adjacent to Dexcom's continuous glucose monitoring franchise. The San Diego-based fund backs startups globally with capital and strategic support.

Ownership category

akta.pro rank

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Venture Capital Investment Returns: As a corporate VC arm of Dexcom, the fund generates returns through equity investments in early-stage healthcare technology companies. Returns are realized through portfolio company exits via IPOs, acquisitions, or secondary sales, supplementing growth in Dexcom's core business while advancing development into chronic health conditions beyond diabetes.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Dexcom Ventures is a corporate venture capital fund that invests equity capital in early-stage healthcare technology companies adjacent to or related to Dexcom's diabetes care strategy. The fund provides portfolio companies with capital investment, strategic partnership, and access to Dexcom's industry expertise, focusing on biosensing, data-driven healthcare, and chronic disease management platforms. Featured disclosed portfolio companies include Medcrypt, Nutromics, Epitel, Signos, BiointelliSense, and Beta Bionics.

Product overview

Dexcom Ventures is a venture capital platform that invests in transformative technology companies in biosensing and data-driven healthcare. Rather than offering a unified product suite, it operates as an investment vehicle backing multiple distinct portfolio companies: Medcrypt (medical device cybersecurity), Nutromics (continuous molecular monitoring), Epitel (seizure monitoring wearables), Signos (AI-driven CGM app), BiointelliSense (remote patient monitoring), and Beta Bionics (iLet Bionic Pancreas insulin delivery). These investments are adjacent to or related to Dexcom's core diabetes care technology business.

Differentiator

Problem solved

Functional benefit

Brands

• Medcrypt: Helping healthcare technology companies ensure medical devices are secure by design. Providing cybersecurity products and strategic management consulting to expedite the go-to-market process of medical device manufacturers' new life-saving connected technologies.
• Nutromics
• Epitel
• Signos
• BiointelliSense
• Beta Bionics

Quantifiable outcome

• Portfolio companies working to increase global access to timely health data for better healthcare and outcomes across populations

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Johnson & Johnson Innovation (JJDC): Largest and longest-running healthcare corporate venture arm, investing across medical devices, diagnostics, and digital health. Directly comparable to Dexcom Ventures as a strategic CVC using parent distribution, clinical, and regulatory assets to accelerate portfolio companies.
• Roche Venture Fund: Roche's CVC arm focused on early-stage diagnostics and digital health. Closely analogous to Dexcom Ventures given the shared biosensing/diagnostics thesis and parent-company strategic backing model.
• Medtronic Ventures: Historical CVC arm of Medtronic that invested in adjacent device, sensor, and digital health technologies. Highly comparable in thesis (device-adjacent strategic investing) to Dexcom Ventures, though now largely wound down.
• Bayer Leaps by Bayer: Bayer's CVC focused on breakthrough health and nutrition platforms with patient-level health-outcome orientation. Comparable as a large-pharma/strategic parent backing transformational health-tech platforms.
• Novartis Venture Fund: Long-standing CVC arm of Novartis investing in early-stage therapeutic and digital health companies. Comparable fund model — corporate-backed venture with strategic-plus-financial return orientation.
• Sanofi Ventures: Sanofi's healthcare CVC that invests in early-stage biotech, digital health, and device-adjacent opportunities. Operates with a similar strategic-CVC playbook to Dexcom Ventures.
• Boston Scientific Ventures: CVC arm of Boston Scientific targeting medical device adjacencies. Directly analogous as a medical-device parent's strategic investment vehicle.
• Intuitive Ventures: CVC of Intuitive Surgical backing data-driven, minimally invasive care and digital surgery platforms. Comparable thesis around data-driven surgical/medical platforms adjacent to a category-leading parent.
• BD (Becton Dickinson) Ventures: Corporate venture arm of Becton Dickinson investing in high-growth medical device, diagnostics, and life sciences opportunities. Similar CVC model backing adjacent device and biosensing innovation.
• Stryker Corporate Development / Ventures: Stryker's strategic investment arm backing medical device, digital health, and surgical innovation startups. Closely parallels Dexcom Ventures as a device-parent CVC investing in adjacent platforms.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dexcom Ventures